Rapidly involuting congenital hemangioma | UniteRare Disease Library

Overview

Rapidly involuting congenital hemangioma (RICH) is a rare benign vascular tumor that is fully developed at birth, distinguishing it from the more common infantile hemangioma, which typically grows after birth. RICH belongs to a group of congenital hemangiomas that also includes non-involuting congenital hemangioma (NICH) and partially involuting congenital hemangioma (PICH). RICH presents as a solitary, raised, violaceous or blue-gray mass, often with a surrounding pale halo, central telangiectasia, or a central depression or ulceration. These tumors most commonly appear on the skin of the head, neck, or limbs, but can occasionally occur in the liver or other organs. Unlike infantile hemangiomas, RICH is negative for the GLUT1 immunohistochemical marker. RICH undergoes rapid spontaneous regression, typically completing involution within 6 to 14 months after birth. During the involution process, the tumor shrinks and may leave behind residual changes such as redundant skin, atrophic skin, subcutaneous fatty tissue loss, or visible veins. In some cases, RICH can be associated with transient thrombocytopenia, mild coagulopathy, or high-output cardiac failure due to arteriovenous shunting, particularly with large lesions. Prenatal diagnosis is sometimes possible through ultrasound, as the tumor is already present and fully formed in utero. Management of RICH is generally conservative, with observation and monitoring being the primary approach, since the natural history involves spontaneous regression. Treatment may be necessary for complications such as significant bleeding, ulceration, heart failure, or hemodynamic instability. In rare cases, surgical excision may be considered for functional impairment, complications, or cosmetic concerns related to residual skin changes after involution. Unlike infantile hemangiomas, RICH does not respond to beta-blocker therapy (such as propranolol). Supportive care and monitoring of platelet counts and coagulation parameters may be warranted in the neonatal period.

Also known as:

RICH

Clinical phenotype terms— hover any for plain English:

Midfrontal capillary hemangiomaHP:0007466Subcutaneous calcificationHP:0007618Perineal hemangiomaHP:0031449Prominent superficial veinsHP:0001015Peripheral arteriovenous fistulaHP:0100784Visceral hemangiomaHP:0410266Hepatic hemangiomaHP:0031207Tufted angiomaHP:0012329

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events

Apr 2026Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy

Spaulding Rehabilitation Hospital — NA

TrialNOT YET RECRUITING

Apr 2026Carbohydrate Fluids and Post Operative Nausea and Vomiting

Boston Medical Center — NA

TrialNOT YET RECRUITING

Apr 2026Anthocyanin-Rich Table Grape Powder for Prophylaxis of Post-Operative Atrial Fibrillation

University of Michigan — PHASE1, PHASE2

TrialRECRUITING

Mar 2026To Determine the Effect of Phaseolean on Glycemic Response to Carbohydrate Rich Meal in Healthy Adult Human Participants

NovoBliss Research Pvt Ltd — NA

TrialNOT YET RECRUITING

Mar 2026The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)

Universiti Kebangsaan Malaysia Medical Centre — PHASE2

TrialRECRUITING

Feb 2026Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and Without Intra-articular Platelet-Rich Plasma Injection.

Lahore General Hospital — PHASE2

TrialRECRUITING

Feb 2026The Effect of Platelet Rich Fibrin On Sensitivity and Periodontal Pockets Distal to Second Molar After Surgical Extraction of Impacted Third Molar

University of Health Sciences Lahore — NA

TrialNOT YET RECRUITING

Feb 2026Effect of Consuming n-3 PUFAs Rich Foods on Triglyceride Concentration and Lipoprotein Composition

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran — NA

TrialRECRUITING

Jan 2026Guided Lateral Sinus Lifting Using Autologous Serum Albumin/Platelet-Rich Fibrin

Kafrelsheikh University — NA

TrialRECRUITING

Jan 2026Comparison Between Transarterial Musculoskeletal Embolization and Platelet-Rich Plasma Injection for the Treatment of Greater Trochanteric Pain Syndrome

Unidade Local de Saúde do Alto Ave, EPE — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Rapidly involuting congenital hemangioma.

20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

20 recruitingView all trials with filters →

Phase 31 trial

Efficacy of Intracavernous Platelet-rich Plasma Injection in the Treatment of Erectile Dysfunction

Phase 3

Active

· Sites: Istanbul, Istanbul · Age: 40–70 yrs

Phase 41 trial

Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease

Phase 4

Actively Recruiting

· Sites: Bilbao, Bizkaia · Age: 18–99 yrs

Phase 23 trials

Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and Without Intra-articular Platelet-Rich Plasma Injection.

Phase 2

Actively Recruiting

· Sites: Lahore, Punjab Province · Age: 18–50 yrs

Comparison Between Transarterial Musculoskeletal Embolization and Platelet-Rich Plasma Injection for the Treatment of Greater Trochanteric Pain Syndrome

Phase 2

Actively Recruiting

PI: Pedro M M Lopes, MD (Unidade Local de Saúde do Alto Ave) · Sites: Guimarães · Age: 18–80 yrs

The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)

Phase 2

Actively Recruiting

PI: Professor Dr. Nur Azlina Mohd Fahami, DVM (Department of Pharmacology, Faculty of Medicine, U) · Sites: Cheras, Kuala Lumpur · Age: 18–65 yrs

N/A11 trials

Microfracture With Platelet Rich Plasma Gel Injection for Osteochondral Lesion of the Talus

N/A

Actively Recruiting

PI: Qinwei Guo, MD (Department of Sports Medicine, Peking University T) · Sites: Beijing · Age: 18–60 yrs

Efficacy of the Entire Papilla Preservation Technique With and Without the Use of L-PRF as a Regenerative Material for the Treatment of Infrabony Defects

N/A

Actively Recruiting

PI: Andreas G Anwandter, DDS (Universidad de Los Andes) · Sites: Santiago, San Bernardo · Age: 18–99 yrs

Effect of Consuming n-3 PUFAs Rich Foods on Triglyceride Concentration and Lipoprotein Composition

N/A

Actively Recruiting

PI: Martha Guevara (INCMNSZ) · Sites: Mexico City, Mexico City · Age: 18–99 yrs

Safety and Efficacy of Platelet-Rich Plasma Combined With Compound Betamethasone in Arthroscopic Surgery for Rotator Cuff Injury With Shoulder Adhesion: A Prospective, Multicenter, Randomized Controlled Trial

N/A

Actively Recruiting

· Sites: Nanchang, Jiangxi · Age: 18–70 yrs

Effect of Platelet-Rich Plasma on Graft Uptake and Postoperative Outcomes in Full-Thickness Skin Grafting of Face and Neck

N/A

Enrolling by Invitation

· Sites: Lahore, Punjab Province · Age: 18–65 yrs

PROTeIn-rich Meals to Control Glucose

N/A

Actively Recruiting

PI: Olga Ramich, PD Dr. (German Institute of Human Nutrition) · Sites: Potsdam, Potsdam-Rehbrücke · Age: 18–75 yrs

Influence of Injectable Platelet Rich Fibrin on Different Orthodontic Tooth Movements During Clear Aligner Therapy

N/A

Enrolling by Invitation

· Sites: Cairo · Age: 15–22 yrs

A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polyphenol-rich Salicornia Extract in the Progression of Cognitive Decline in a Cohort of Patients With Lacunar Infarcts (SALACUNAR)

N/A

Actively Recruiting

· Sites: Seville · Age: 40–90 yrs

Post Extraction Changes After Alveolar Socket Preservation Using Autogenous Dentin Graft (ADG) Combined With Either Albumin Platelet-rich Fibrin (ALB-PRF) or Standard Platelet-rich Fibrin (PRF).

N/A

Actively Recruiting

PI: Enas Ahmed Elgendy, PhD (Kaferelsheikh University) · Sites: Kafr ash Shaykh, Kafrelsheikh · Age: 18–60 yrs

Metabolic Effects of Linoleic Acid-Rich Oil Compared to a Blend Oil in Adults With Insulin Resistance

N/A

Actively Recruiting

PI: Loni Berkowitz, PhD (Pontificia Universidad Catolica de Chile) · Sites: Santiago, Santiago Metropolitan · Age: 20–60 yrs

Treatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts

N/A

Actively Recruiting

· Sites: Istanbul, Üsküdar · Age: 18–65 yrs

Other2 trials

REASSURE-NIRS Registry

Actively Recruiting

PI: Yu Kataoka, MD (National Cerebral & Cardiovascular Center) · Sites: Miyazaki; Suita · Age: 20–95 yrs

Evaluation of Periapical Healing Following Endodontic Microsurgery With Leukocyte and Platelet Rich Fibrin (L-PRF)

Actively Recruiting

· Sites: Philadelphia, Pennsylvania · Age: 18–99 yrs

Specialists

18 foundView all specialists →

GI

Gözde Işık

Specialist

Osteonecrosis of the jaw

PI on 2 active trials1 Rapidly involuting congenital hemangioma publication

Overview

FDA & Trial Timeline

Treatments

Clinical Trials

Specialists

Treatment Centers

Travel Grants

Community

Latest news about Rapidly involuting congenital hemangioma

Caregiver Resources

Common questions about Rapidly involuting congenital hemangioma